When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations cause it, and the condition progressively gets worse over time.
[content-module:CompanyOverview|NASDAQ:SLDB]Currently, the only Food and Drug Administration (FDA)-approved gene therapy to treat DMD is ELEVIDYS. Biotech company Sarepta Therapeutics (NASDAQ: SRPT) makes the drug. Since the company began selling ELEVIDYS, it has experienced rapid sales growth. The firm nearly tripled ELEVIDYS sales from Q4 2023 to Q4 2024, with revenue coming in at $384 million last quarter.
